Paper38534720
Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species and Pseudomonas aeruginosa.
Ferous S and 4 others. Antibiotics (Basel), 2024. Cited by 25 papers, by iCite.
Cite this record
ConductScience Library. Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species and Pseudomonas aeruginosa. Papers, record 38534720. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38534720
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Antimicrobial and Diagnostic Stewardship of the Novel β-Lactam/β-Lactamase Inhibitors for Infections Due to Carbapenem-Resistant Enterobacterales Species and Pseudomonas aeruginosa.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References122
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24041554 | Evaluation of Etest® strips for detection of KPC and metallo-carbapenemases in Enterobacteriaceae. | Diagn Microbiol Infect Dis | 2013 | https://conductscience.org/library/papers/24041554 | PubMed |
| 2 | 36878411 | In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020. | Int J Antimicrob Agents | 2023 | https://conductscience.org/library/papers/36878411 | PubMed |
| 3 | 31365094 | Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo. | J Antimicrob Chemother | 2019 | https://conductscience.org/library/papers/31365094 | PubMed |
| 4 | 30649310 | In vitro synergistic activity of meropenem/vaborbactam in combination with ceftazidime/avibactam against KPC-producing Klebsiella pneumoniae. | J Antimicrob Chemother | 2019 | https://conductscience.org/library/papers/30649310 | PubMed |
| 5 | 37004964 | Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis. | Microb Pathog | 2023 | https://conductscience.org/library/papers/37004964 | PubMed |
| 6 | 27927915 | Comparative Evaluation of Four Phenotypic Tests for Detection of Carbapenemase-Producing Gram-Negative Bacteria. | J Clin Microbiol | 2017 | https://conductscience.org/library/papers/27927915 | PubMed |
| 7 | 22057701 | β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. | Clin Infect Dis | 2012 | https://conductscience.org/library/papers/22057701 | PubMed |
| 8 | 22649010 | Imported Klebsiella pneumoniae carbapenemase-producing K. pneumoniae clones in a Greek hospital: impact of infection control measures for restraining their dissemination. | J Clin Microbiol | 2012 | https://conductscience.org/library/papers/22649010 | PubMed |
| 9 | 36943617 | Real-Life Data on the Effectiveness and Safety of Cefiderocol in Severely Infected Patients: A Case Series. | Infect Dis Ther | 2023 | https://conductscience.org/library/papers/36943617 | PubMed |
| 10 | 28951106 | In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. | Int J Infect Dis | 2017 | https://conductscience.org/library/papers/28951106 | PubMed |
| 11 | 37764003 | First Detection and Molecular Characterization of Pseudomonas aeruginosa blaNDM-1 ST308 in Greece. | Microorganisms | 2023 | https://conductscience.org/library/papers/37764003 | PubMed |
| 12 | 35052925 | NDM Production as a Dominant Feature in Carbapenem-Resistant Enterobacteriaceae Isolates from a Tertiary Care Hospital. | Antibiotics (Basel) | 2021 | https://conductscience.org/library/papers/35052925 | PubMed |
| 13 | 16251324 | Kinetics study of KPC-3, a plasmid-encoded class A carbapenem-hydrolyzing beta-lactamase. | Antimicrob Agents Chemother | 2005 | https://conductscience.org/library/papers/16251324 | PubMed |
| 14 | 30216371 | Rapid detection of NDM, KPC and OXA-48 carbapenemases directly from positive blood cultures using a new multiplex immunochromatographic assay. | PLoS One | 2018 | https://conductscience.org/library/papers/30216371 | PubMed |
| 15 | 33199392 | Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: Results of the GERPA Multicenter Study. | Antimicrob Agents Chemother | 2021 | https://conductscience.org/library/papers/33199392 | PubMed |
| 16 | 9055993 | Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein. | Antimicrob Agents Chemother | 1997 | https://conductscience.org/library/papers/9055993 | PubMed |
| 17 | 30020449 | Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations. | Clin Infect Dis | 2019 | https://conductscience.org/library/papers/30020449 | PubMed |
| 18 | 31863899 | Resistance to ceftazidime-avibactam and underlying mechanisms. | J Glob Antimicrob Resist | 2020 | https://conductscience.org/library/papers/31863899 | PubMed |
| 19 | 34268382 | Carbapenemase detection by NG-Test CARBA 5-a rapid immunochromatographic assay in carbapenem-resistant Enterobacterales diagnosis. | Ann Transl Med | 2021 | https://conductscience.org/library/papers/34268382 | PubMed |
| 20 | 35900090 | Increased Expression and Amplification of blaKPC-2 Contributes to Resistance to Ceftazidime/Avibactam in a Sequence Type 11 Carbapenem-Resistant Klebsiella pneumoniae Strain. | Microbiol Spectr | 2022 | https://conductscience.org/library/papers/35900090 | PubMed |
Cited by25
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42938753 | In Vitro and In Vivo Efficacy of the Broad-Spectrum β-Lactamase Inhibitor APC24-7 in Combination with Meropenem Against Carbapenem-Resistant Enterobacterales. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42938753 | PubMed |
| 42938727 | Carbapenemases in Gram-Negative Bacilli: Classification, Detection, Therapeutic Options, and Resistance to Novel Antimicrobials. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42938727 | PubMed |
| 42923582 | Resistance profile and clinical outcomes of Xuebijing injection combined with antibiotics for carbapenem-resistant Pseudomonas aeruginosa infection: a single-center retrospective cohort study. | Am J Transl Res | 2026 | https://conductscience.org/library/papers/42923582 | PubMed |
| 42868159 | Investigation on the use of ceftazidime-avibactam at a national hospital in Vietnam. | PLoS One | 2026 | https://conductscience.org/library/papers/42868159 | PubMed |
| 42795452 | Carbapenem-Resistant Klebsiella pneumoniae in Healthcare-Associated Infections: Global and Regional Epidemiology, Resistance Mechanisms, and Therapeutic Strategies, with Particular Attention to Romania and Eastern Europe (2020-2025). | Microorganisms | 2026 | https://conductscience.org/library/papers/42795452 | PubMed |
| 42560298 | Multidrug-Resistant Salmonella and Shigella: Epidemiology, Resistance Mechanisms, and Emerging Therapeutic Strategies. | Pol J Microbiol | 2026 | https://conductscience.org/library/papers/42560298 | PubMed |
| 42238879 | Identification of a novel natural compound inhibitor targeting AmpC β-lactamase to combat multidrug-resistant Pseudomonas aeruginosa. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42238879 | PubMed |
| 41897305 | A High-Affinity Nanobody Selectively Recognizing KPC-2/KPC-3: Biochemical and Structural Insights. | Biomolecules | 2026 | https://conductscience.org/library/papers/41897305 | PubMed |
| 41246002 | bla IMP-45 Amplification Facilitates Heterogeneous Resistance to Imipenem in Pseudomonas aeruginosa. | Infect Drug Resist | 2025 | https://conductscience.org/library/papers/41246002 | PubMed |
| 41117673 | The Achilles' heel of the Trojan Horse? A systematic evaluation of cefiderocol susceptibility testing. | J Antimicrob Chemother | 2025 | https://conductscience.org/library/papers/41117673 | PubMed |
| 41024947 | Antimicrobial dosing considerations in critically ill patients with acute kidney injury: A review. | World J Nephrol | 2025 | https://conductscience.org/library/papers/41024947 | PubMed |
| 41023351 | Detection of colistin resistance from Escherichia colicolonies grown on agar cultures and bacterial pellets obtained from positively flagged blood cultures by MALDI-TOF MS-based rapid assay: aproof-of-concept study. | Eur J Clin Microbiol Infect Dis | 2025 | https://conductscience.org/library/papers/41023351 | PubMed |
| 41009877 | Epidemiological Trends of Carbapenemase-Producing Pseudomonas aeruginosa in a Tertiary Care Hospital in Athens, Greece, During 2020-2023. | Antibiotics (Basel) | 2025 | https://conductscience.org/library/papers/41009877 | PubMed |
| 41001706 | Comparative evaluation of disc diffusion and broth microdilution methods for aztreonam/avibactam susceptibility testing in Enterobacterales. | J Antimicrob Chemother | 2025 | https://conductscience.org/library/papers/41001706 | PubMed |
| 40827922 | Establishing the reference broth microdilution MIC method for cefepime-taniborbactam. | J Clin Microbiol | 2025 | https://conductscience.org/library/papers/40827922 | PubMed |
| 40761277 | Global prevalence and antibiotic resistance profiles of carbapenem-resistant Pseudomonas aeruginosa reported from 2014 to 2024: a systematic review and meta-analysis. | Front Microbiol | 2025 | https://conductscience.org/library/papers/40761277 | PubMed |
| 40558206 | Oxacillin-Supplemented Mueller-Hinton Agar for In Vitro Inhibition of Ambler Class C β-Lactamases in Enterobacterales. | Antibiotics (Basel) | 2025 | https://conductscience.org/library/papers/40558206 | PubMed |
| 40558176 | Challenges of Carbapenem-Resistant Enterobacteriaceae in the Development of New β-Lactamase Inhibitors and Antibiotics. | Antibiotics (Basel) | 2025 | https://conductscience.org/library/papers/40558176 | PubMed |
| 40422861 | Comprehensive analysis of extensive drug-resistant Salmonella Typhi in Gujarat region, India: genomic findings and prospective alternative therapy. | Microbiol Spectr | 2025 | https://conductscience.org/library/papers/40422861 | PubMed |
| 40278619 | Deciphering Multidrug-Resistant Pseudomonas aeruginosa: Mechanistic Insights and Environmental Risks. | Toxics | 2025 | https://conductscience.org/library/papers/40278619 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38534720
GET https://conductscience.org/api/papers/v1/38534720/references?page=2